Mantle Cell Lymphoma Clinical Trials in Boston

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
I
A Safety and Pharmacokinetic Study of IGM-2323 in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma
Recruiting
  • Non-Hodgkin Lymphoma
  • +4 more
  • Duarte, California
  • +12 more
2022-03-24
Mar 24, 2022
J
A Long-term Extension Study of PCI-32765 (Ibrutinib)
Enrolling by invitation
  • Chronic Lymphocytic Leukemia
  • +6 more
  • Duarte, California
  • +165 more
2022-03-24
Mar 24, 2022
C
Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma
Active, not recruiting
  • Adult Immunoblastic Lymphoma
  • +12 more
  • Cytology Specimen Collection Procedure
  • Birmingham, Alabama
  • +129 more
2022-03-23
Mar 23, 2022
C
A Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor, in B-Cell Malignancies and Advanced Solid Tumors
Recruiting
  • Malignancy
  • +14 more
  • Scottsdale, Arizona
  • +17 more
2022-03-07
Mar 7, 2022
L
A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL
Recruiting
  • Chronic Lymphocytic Leukemia
  • +5 more
  • Scottsdale, Arizona
  • +55 more
2022-01-12
Jan 12, 2022
E
Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission
Recruiting
  • CD20 Positive
  • Mantle Cell Lymphoma
  • Autologous Hematopoietic Stem Cell Transplantation
  • +2 more
  • Birmingham, Alabama
  • +318 more
2021-12-22
Dec 22, 2021
M
Double Cord Versus Haploidentical (BMT CTN 1101) - 2020
Completed
Has Results
  • Acute Lymphocytic Leukemia
  • +6 more
  • Haploidentical Bone Marrow Transplant
  • Double Umbilical Cord Blood Transplant
  • Birmingham, Alabama
  • +38 more
2021-11-02
Nov 2, 2021
D
A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL
Active, not recruiting
Has Results
  • Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
  • Mantle Cell Lymphoma
  • Monterey, California
  • +5 more
2021-09-06
Sep 6, 2021
A
APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL)
Active, not recruiting
  • Non Hodgkin Lymphoma
  • +2 more
  • APR-246 (eprenetapopt) + Acalabrutinib in CLL
  • +3 more
  • Boston, Massachusetts
  • +3 more
2021-09-17
Sep 17, 2021
A
Bortezomib After Combination Chemotherapy, Rituximab, and an Autologous Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma
Active, not recruiting
Has Results
  • Mantle Cell Lymphoma
  • San Francisco, California
  • +47 more
2021-08-16
Aug 16, 2021
A
Avo In R/R And Previously Untreated MCL
Recruiting
  • Mantle Cell Lymphoma
  • Refractory Lymphoma
  • Boston, Massachusetts
  • +1 more
2021-08-05
Aug 5, 2021
A
A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies - 2016
Completed
  • Chronic Lymphoid Leukemia
  • +5 more
  • Los Angeles, California
  • +11 more
2021-07-28
Jul 28, 2021
A
Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma
Recruiting
  • Mantle Cell Lymphoma
  • B Cell Lymphoma
  • Duarte, California
  • +10 more
2021-07-19
Jul 19, 2021
D
Rituximab/Bendamustine + Rituximab/Cytarabine for Mantle Cell Lymphoma
Active, not recruiting
Has Results
  • Mantle Cell Lymphoma
  • Boston, Massachusetts
  • +2 more
2021-06-09
Jun 9, 2021
D
CONFIRM: Magnetic Resonance Guided Radiation Therapy
Recruiting
  • Gastric Cancer
  • +5 more
  • Viewray MRIdian® Linac
  • Boston, Massachusetts
  • +1 more
2021-05-28
May 28, 2021
M
Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma
Active, not recruiting
Has Results
  • Follicular Lymphoma
  • +9 more
  • Boston, Massachusetts
  • +1 more
2021-01-18
Jan 18, 2021
G
Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies - 2020
Terminated
Has Results
  • Chronic Lymphocytic Leukemia
  • +4 more
  • Entospletinib MM
  • Entospletinib SDD
  • Birmingham, Alabama
  • +47 more
2020-11-02
Nov 2, 2020
P
Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia - 2019
Completed
Has Results
  • B-cell Chronic Lymphocytic Leukemia
  • +9 more
  • Stanford, California
  • +15 more
2020-05-14
May 14, 2020
J
Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product - 2018
Terminated
  • Non Hodgkin Lymphoma
  • +5 more
  • JCAR017
  • JCARH125
  • Duarte, California
  • +1 more
2020-04-30
Apr 30, 2020
C
A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial - 2017
Completed
Has Results
  • Mantle Cell Lymphoma
  • Little Rock, Arkansas
  • +69 more
2018-12-11
Dec 11, 2018
M
Carfilzomib Plus Belinostat in Relapsed/Refractory NHL - 2018
Completed
  • Non-Hodgkin Lymphoma
  • +4 more
  • Boston, Massachusetts
  • +2 more
2018-01-23
Jan 23, 2018
J
A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy - 2015
Completed
  • Mantle Cell Lymphoma
  • La Jolla, California
  • +56 more
2016-05-27
May 27, 2016
D
Chemotherapy Followed by Zevalin for Relapsed Mantle Cell Lymphoma - 2013
Completed
  • Mantle Cell Lymphoma
  • Boston, Massachusetts
  • +1 more
2014-04-22
Apr 22, 2014
A
Phase II Safety and Efficacy Study of Single-agent AT-101 in Patients With Relapsed or Refractory B-cell Malignancies - 2008
Completed
  • Follicular Lymphoma
  • +4 more
  • Birmingham, Alabama
  • +10 more
2011-06-24
Jun 24, 2011